Related Experiment Videos
Caspase-3 activation in systemic anaplastic large-cell lymphoma
Elias Drakos1, George Z Rassidakis, Raymond Lai
1Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Summary
Anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma (ALCL) cells undergo programmed cell death via caspase-3 activation when treated with doxorubicin. Activated caspase-3 levels are higher in ALK-positive ALCL tumors.
Area of Science:
- Oncology
- Cell Biology
- Molecular Biology
Background:
- Anaplastic large-cell lymphoma (ALCL) is categorized by chromosome 2p23 abnormalities leading to anaplastic lymphoma kinase (ALK) overexpression.
- Previous research indicated differences in apoptosis rates and related proteins between ALK-positive and ALK-negative ALCL.
Purpose of the Study:
- To investigate the role of activated caspase-3 (aC-3) in ALCL cell death.
- To assess aC-3 expression in ALCL cell lines and patient tumors.
- To determine the effect of doxorubicin treatment on caspase-3 activation in ALCL cells.
Main Methods:
- Utilized ALCL cell lines (Karpas 299, SU-DHL-1) and caspase inhibitors (Boc-D-FMK, DEVD-FMK).
- Assessed cell viability and apoptosis using trypan blue and Annexin-V assays.
- Quantified caspase-3 enzymatic activity and evaluated aC-3 expression via immunohistochemistry in 57 ALCL tumors.
Main Results:
- Doxorubicin treatment significantly increased caspase-3 activity in ALCL cells, which was blocked by caspase inhibitors.
- Mean aC-3 expression was higher in ALK-positive ALCL (3.2%) compared to ALK-negative ALCL (1.2%).
- aC-3 expression showed an inverse correlation with BCL-2 expression but did not correlate with patient outcomes.
Conclusions:
- Doxorubicin-induced cell death in ALK-positive ALCL involves caspase-3 activation.
- Activated caspase-3 levels correlate with ALK expression in ALCL tumors.
- Caspase-3 activation is a key mechanism in the response of ALK-positive ALCL to doxorubicin.